JOP20190275A1 - طرق وتركيبات لعلاج اضطراب إسهال خِلقي - Google Patents

طرق وتركيبات لعلاج اضطراب إسهال خِلقي

Info

Publication number
JOP20190275A1
JOP20190275A1 JOP/2019/0275A JOP20190275A JOP20190275A1 JO P20190275 A1 JOP20190275 A1 JO P20190275A1 JO P20190275 A JOP20190275 A JO P20190275A JO P20190275 A1 JOP20190275 A1 JO P20190275A1
Authority
JO
Jordan
Prior art keywords
methods
compositions
disorder
treating congenital
cdd
Prior art date
Application number
JOP/2019/0275A
Other languages
English (en)
Inventor
A Conte Lisa
R Chaturvedi Pravin
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of JOP20190275A1 publication Critical patent/JOP20190275A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

غير متوفر
JOP/2019/0275A 2017-05-31 2017-06-16 طرق وتركيبات لعلاج اضطراب إسهال خِلقي JOP20190275A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513251P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
JOP20190275A1 true JOP20190275A1 (ar) 2019-11-27

Family

ID=64455032

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0275A JOP20190275A1 (ar) 2017-05-31 2017-06-16 طرق وتركيبات لعلاج اضطراب إسهال خِلقي

Country Status (9)

Country Link
US (1) US11857510B2 (ar)
EP (1) EP3634581A4 (ar)
JP (1) JP2020525407A (ar)
CN (1) CN110831667A (ar)
AU (1) AU2018278312A1 (ar)
CA (1) CA3065797A1 (ar)
IL (1) IL270984A (ar)
JO (1) JOP20190275A1 (ar)
WO (1) WO2018222919A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE36448T1 (de) 1985-08-30 1988-09-15 Nestle Sa Diaetetisches produkt mit blutreinigender und antidiarrhoel-wirksamkeit und verfahren zu seiner zubereitung.
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007130893A2 (en) 2006-05-01 2007-11-15 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
EP2241318B1 (en) 2006-05-01 2012-12-19 Napo Pharmaceuticals, Inc. Method for treatment of constipation-predominant irritable bowel syndrome
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
BR112013010774A2 (pt) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
WO2017112953A1 (en) 2015-12-23 2017-06-29 Vanessa Research, Inc. Compositions and methods of treatment for mvid and related diseases
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة

Also Published As

Publication number Publication date
EP3634581A4 (en) 2021-02-24
US11857510B2 (en) 2024-01-02
IL270984A (en) 2020-01-30
WO2018222919A1 (en) 2018-12-06
JP2020525407A (ja) 2020-08-27
AU2018278312A1 (en) 2020-01-02
EP3634581A1 (en) 2020-04-15
CN110831667A (zh) 2020-02-21
US20200108047A1 (en) 2020-04-09
CA3065797A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
MX2021005365A (es) Preparaciones y composiciones de oligosacaridos.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MY173960A (en) Compositions for balancing gut microbiota and the preparation and the uses thereof
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
EA202190927A1 (ru) Иммуноаблативные виды терапии
MX2013004062A (es) Analogos de ciclosporina.
EA202090732A1 (ru) Составы для трансдермального введения
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
PH12021551075A1 (en) A NUTRITIONAL COMPOSITION COMPRISING METABOLITES OF HMOs TO IMPROVE THE GASTROINTESTINAL BARRIER
JOP20190275A1 (ar) طرق وتركيبات لعلاج اضطراب إسهال خِلقي
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
PH12016500025A1 (en) Methods for promoting neuronal development and/or health
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
PH12015502100A1 (en) Reducing the risk of autoimmune disease
BR112017024065A2 (pt) método para tratar insuficiência cardíaca avançada em um indivíduo humano